Join
Live feed
·
PRReleasevia Quantisnow
Valneva SE logo

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

ByQuantisnow·Wall Street's wire, on your screen.
VALN· Valneva SE
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VALN (Valneva SE) and more on Quantisnow.